NAMA
ALXN

Nikko Asset Management Americas’s Alexion Pharmaceuticals ALXN Stock Holding History

Nikko Asset Management Americas’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,200
Closed -$297K – 243
2016
Q1 		$297K Buy
+2,200
New +$323K 0.04% 190

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nikko Asset Management Americas's ALXN Position: Q2 2016 in Review

Nikko Asset Management Americas sold out of Alexion Pharmaceuticals (ALXN) in Q2 2016, closing a stake of 2,200 shares — an estimated $297K sold.

Nikko Asset Management Americas first reported a position in ALXN in Q1 2016 and held it in 1 quarter. The position peaked at $297K in Q1 2016. 533 funds tracked by Wall St. Rank hold ALXN as of Q2 2016.

  • Nikko Asset Management Americas reported no remaining Alexion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Nikko Asset Management Americas sold 2,200 Alexion Pharmaceuticals shares in Q2 2016, an estimated $297K.
  • Nikko Asset Management Americas first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Nikko Asset Management Americas's Alexion Pharmaceuticals position peaked at $297K in Q1 2016.
  • 533 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2016.

Based on Nikko Asset Management Americas's 13F filing for Q2 2016, filed 19 Jul 2016.